Accessibility Menu
C4 Therapeutics logo

C4 Therapeutics(NASDAQ) CCCC

Market Cap$473.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-85%
5 Year-91%
1 Year+51%
1 Month+9%
Premium Feature
Moneyball Superscore
58/100
$3.86
-5.98%
-0.25Today
After hours$3.88+$0.02 (+0.52%)
C4 Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.852026-08-28
C4 Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.75%USD 4.002026-08-21
1 month+9.38%USD 3.522026-07-29
3 month-11.9%USD 4.372026-05-29
Year to date+101.57%USD 1.912025-12-31
1 year+50.98%USD 2.552025-08-28
3 year+25.41%USD 3.072023-08-29
5 year-90.73%USD 41.542021-08-27
Since inception-84.9%USD 25.492020-10-02

C4 Therapeutics Financials at a Glance

Market Cap

$473.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$35.04M

Net Income (TTM)

-$101.42M

EPS (TTM)

-$1.00

P/E Ratio

-3.85

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$3.86

Volume

1,828,731.928

Open

$4.07

Previous Close

$3.85

Daily Range

$3.83 - $4.10

52-Week Range

$1.69 - $5.17

Estimated Earnings Date

Nov 5, 2026

CCCC News

Two people participating in a telehealth session

Why C4 Therapeutics Stock Crushed the Market on Monday

Eric VolkmanSep 15, 2025
Foolcom-Featured.png

CCCC Revenue Drops 46%

Motley Fool Markets TeamAug 7, 2025

CCCC: Motley Fool Moneyball Superscore

58

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About C4 Therapeutics

C4 Therapeutics, Inc. makes medicines that destroy harmful proteins. These drugs help patients with cancer and brain disorders. They use the body's natural system to remove disease triggers.

How C4 Destroys Disease Proteins

  • Cemsidomide (Blood Cancer): An oral medicine for multiple myeloma that targets specific proteins; currently in Phase 2 clinical trials.
  • Lung Cancer Medicine: A selective treatment for non-small cell lung cancer currently in human trials in Greater China.
  • Solid Tumor Candidates: Compounds designed to treat melanoma and other cancers by linking disease proteins to the body's disposal system.
  • Neurological Research: Early-stage programs focusing on inflammation and brain diseases using drugs that can cross the blood-brain barrier.

A Strategy of Global Collaboration

  • Partnered with Roche in April 2026 to develop new protein degraders through a new research agreement.
  • Achieved a $2.0 million milestone under a collaboration with Biogen during the first six months of 2026.
  • Licensed development rights for a lung cancer drug to Betta Pharma in May 2023.
  • Terminated a research collaboration with Merck in 2025 while prioritizing other internal projects.

What Makes Their Technology Different?

The company uses its proprietary technology platform to design small molecules that can reach the brain. This system helps create medicines for diseases that were previously difficult to treat with traditional drugs.

The Latest Financial Results

  • Total revenue reached $6.6 million for the three months ended June 30, 2026.
  • Research and development expenses were $49.1 million for the six-month period ended June 30, 2026, down from $53.3 million in the prior year period.
  • The company held $300.4 million in cash and marketable securities as of June 30, 2026.
  • Market capitalization rose to $610.4 million in Q2 2026, up 501.1% year over year.

Bottom Line

C4 Therapeutics has moved from early research to testing multiple drug candidates in human trials. It maintains its operations through strategic partnerships and equity offerings while advancing its protein-destroying technology.

AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

104

CEO

Andrew J. Hirsch, MBA

Website

www.c4therapeutics.com

Headquarters

Watertown, MA 02472, US

CCCC Financials

Key Financial Metrics (TTM)

Gross Margin

94.86%

Operating Margin

-318.97%

Net Income Margin

-289.44%

Return on Equity

-45.45%

Return on Capital

-33.01%

Return on Assets

-28.22%

Earnings Yield

-25.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$473.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

123.03M

Volume

1.83M

Avg. Volume

3.08M

Financials (TTM)

Gross Profit

$33.24M

Operating Income

-$111.77M

EBITDA

-$98.31M

Operating Cash Flow

-$84.87M

Capital Expenditure

-$523.00K

Free Cash Flow

-$85.39M

Cash & ST Invst.

$253.66M

Total Debt

$56.86M

C4 Therapeutics Performance Analysis

C4 Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 31,096,000-32.1%
20232023-12-31USD 20,756,000-33.3%
20242024-12-31USD 35,584,00071.4%
20252025-12-31USD 35,947,0001.0%
C4 Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3073.8%
Q42025-12-31-1.9%
Q12026-03-31-44.2%
Q22026-06-307.9%
C4 Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.6244.0%
20232023-12-31USD -2.671.7%
20242024-12-31USD -1.52-43.1%
20252025-12-31USD -1.27-16.6%
C4 Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-18.9%
Q42025-12-3159.1%
Q12026-03-31-11.1%
Q22026-06-3010.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$6.64M

+2.8%

Gross Profit

$6.64M

+2.8%

Gross Margin

100.00%

N/A

Market Cap

$473.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.55M

N/A

Employees

104

N/A

Net Income

-$23.64M

+9.2%

EBITDA

-$23.34M

+8.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$253.66M

+18.2%

Total Debt

$56.86M

-9.6%

Accounts Receivable

$1.33M

-38.2%

Inventory

$0.00

N/A

Long Term Debt

$50.18M

-11.7%

Short Term Debt

$6.68M

+10.1%

Return on Assets

-28.22%

N/A

Return on Invested Capital

-35.92%

N/A

Free Cash Flow

-$1.61M

+86.8%

Operating Cash Flow

-$1.57M

+86.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OABIOmniAb, Inc.
$4.47-3.04%
PEPGPepGen Inc.
$3.08+0.33%
CDXSCodexis, Inc.
$1.59-4.22%
MOLNMolecular Partners AG
$4.50-3.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$217.55-0.05%
PCGPG&E
$16.60-0.08%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45-0.03%
IRENIren
$35.45-0.13%

Questions About CCCC

What is the current price of C4 Therapeutics?

C4 Therapeutics is trading at $3.85 per share.

What is the 52-week range for C4 Therapeutics?

Over the past 52 weeks, C4 Therapeutics has traded between $1.69 and $5.17.

How much debt does C4 Therapeutics have?

As of the most recent reporting period, C4 Therapeutics reported total debt of $56.86M.

How much cash does C4 Therapeutics have on hand?

C4 Therapeutics reported $78.61M in cash and cash equivalents in its most recent financial results.

What is C4 Therapeutics’s dividend yield?

C4 Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services